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Introduction
Optical coherence tomography angiography (OCT-A) has recently emerged as a novel tool for imaging and evaluating the retinal microvasculature. The mechanism behind OCT-A involves performing multiple rapid B-scans and analyzing the variations in intensity and reflectivity of the signal caused by red blood cell movement to create flow maps of the microvasculature. 1, 2 OCT-A is considered to be an adjunct to traditional imaging modalities, such as fluorescein angiography (FA), given its non-invasive nature and ability to produce high-resolution images of the vessels' individual layers, including the superficial, deep and choroidal capillary plexuses. 3 Currently, the most common clinical applications of OCT-A involve the evaluation of chorioretinal vascular diseases, such as diabetic retinopathy (DR), age-related macular degeneration (AMD), retinal vein occlusion (RVO), macular telangiectasia (MacTel) and other causes of choroidal neovascularization. [4] [5] [6] [7] OCT-A has also been increasingly utilized in the diagnosis of optic neuropathies and glaucoma. [8] [9] [10] Currently, several OCT-A devices are commercially available that employ unique analytic techniques. Though previous research has shown the clinical applications of OCT-A in detecting various chorioretinal diseases, 1,5 these studies primarily focus on one OCT-A device and thus lack a comparison across multiple devices. Additionally, although few publications exist that compare OCT-A devices, a lack of standardization in study designs, data analysis, and artifacts precludes reaching a consensus. 11 Relationships of vascular metrics across different devices will likely be important for large clinical trials occurring at multiple centers with a variety of OCT-A platforms.
Previous comparison studies have established that differences in foveal avascular zone (FAZ) area and vessel density (VD) are parameters of particular clinical significance, as they are abnormal in retinal vascular disease. 3, 11, 12 Thus, the aim of this study was to quantitatively compare FAZ and VD metrics across the following three OCT-A platforms at a single center.
Methods

Patient Selection
This study was a retrospective review of images from three OCT-A devices that was approved and carried out in accordance with the Institutional Review Board (IRB) guidelines set forth by the Massachusetts Eye and Ear Human Studies Committee. This study adhered to the tenets of the Declaration of Helsinki. A written informed consent was obtained from each study subject. All patients were imaged on the following three devices: Optovue RTVue-XR (Optovue Inc, Fremont, California, USA), Topcon DRI-OCT Triton Swept-Source OCT (Topcon, Japan), and Zeiss Cirrus 5000-HD-OCT Angioplex (Zeiss Meditec. Inc, Germany) ( Table 1 ).
Thirteen eyes from seven patients at the Massachusetts Eye and Ear (MEE) Retina Service were included in the study. The subjects had a diagnosis of either age-related macular degeneration (AMD), aneurismal type 1 neovascularization (Aneurismal Type 1 NV), central serous retinopathy (CSR), MacTel, or choroidal neovascular membranes (CNVM) ( Table 2 ). [13] [14] [15] [16] The exclusion criteria included patients with any history of diabetes mellitus or chronic kidney disease.
Imaging
Subjects were scanned on each of the following three OCT-A devices: Optovue Avanti Angiovue, Topcon DRI-OCT Triton Swept-Source OCT, and Zeiss Cirrus 5000-HD-OCT Angioplex. For each patient, pupillary dilation was completed and the OCT-A imaging on each device was performed using a 3x3mm 2 or a 6x6mm 2 volume scan pattern centered on the fovea. Furthermore, an image of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) was generated for each eye using automated layer segmentation, corrected by manual readjustments of the segmentation lines ( Figure 1 ). Imaging processing was performed using ImageJ software (National Institutes of Health, Maryland, USA). Two investigators (YL, JCW) separately and independently measured FAZ area at the SCP. The FAZ border was manually outlined. The surface area was measured in square pixels and was converted to square millimeters using the formula: FAZ area (mm 2 ) = FAZ area (pixel 2 )/ total surface area (pixel 2 ) * total surface area (mm 2 ). In addition, SCP and DCP images were binarized using the Niblack automated local thresholding method ( Figure 2 ). VD is defined as the percentage of total area that is occupied by blood vessels. 17 For each SCP and DCP image, the total surface area occupied by blood vessels was measured by the ImageJ software, while VD was the percentage calculated by dividing the total surface area of the image.
Statistical Analysis
The JASP software (University of Amsterdam, Amsterdam, Noord-Holland) was utilized for statistical analysis. To analyze for differences among the individual devices, a repeated measures ANOVA and a post-hoc test were performed. In addition, interclass correlation coefficient (ICC) and Bland-Altman plots were employed to measure the repeatability of the data. P-values were Bonferroni corrected and a value of less than 0.05 was considered to be significant.
Results
Thirteen eyes from seven patients with a history of either AMD, CSR, MacTel, Aneurismal Type 1 NV, or CNVM were included in the study ( Table 2 ). The mean age was 67 ± 11 years old, while the gender distribution was three females and four males. The ethnicity of all included individuals was Caucasian.
The mean SCP FAZ area for the Triton device was 0.161 ± 0.103 mm 2 , Angiovue device was 0.161 ± 0.106 mm 2 , and for the Angioplex device was 0.164 ± 0.100 mm 2 The ICC for the FAZ area measurements was found to be 0.95 ( Table 3 ). Comparison of SCP FAZ area measurements revealed no significant differences across the devices (p = 0.792). Bland-Altman plots showed agreement between the two investigators and three devices measuring the FAZ area ( Figure 3 ).
The mean VD for the Angiovue device was 0.307 ± 0.013 at the SCP and 0.332 ± 0.025 at the DCP, for the Triton device was 0.340 ± 0.014 at the SCP and 0.334 ± 0.009 at the DCP, and for the Angioplex device was 0.352 ± 0.014 at the SCP and 0.364 ± 0.012 at the DCP (Table 4 ). Repeated measures ANOVA comparing the three devices revealed that a significant difference existed. Paired comparisons via post-hoc tests indicated a significant difference in the SCP VD between all of the devices: Triton 0.340 ± 0.014, Angiovue 0.307 ± 0.013, Angioplex 0.352 ± 0.014, p < 0.05. For the DCP, a significantly greater VD was observed with Angioplex (0.364 ± 0.012, p < 0.05) in comparison to both Triton (0.334 ± 0.009) and Angiovue (0.332 ± 0.025) ( Table 5 ).
Discussion
OCT-A is a nascent non-invasive technology that has been increasingly incorporated into clinical ophthalmology. In particular, this imaging modality offers a novel field of study given the utility of OCT-A devices in detecting various retinal and choroidal diseases. 18 There are several core macular microvasculature metrics now readily accessible on a variety of available OCT-A devices. Though previous investigators have compared the use of different combinations of OCT-A metrics, we found no existing publications that compare these three included OCT-A devices in chorioretinal diseases. 3, 11, 18, 19 As FAZ and VD have been shown to be abnormal in retinal vascular disease, this study focuses on comparing these two metrics in retinopathies across three OCT-A devices (Angiovue, Triton, and Angioplex). 12 The results of this study indicate that while FAZ area could be reliably measured across all three devices, statistically significant differences were found in the VD metric for both the SCP and DCP layers, especially for the Angioplex device. Our findings regarding FAZ area is consistent with Chung et al who found no significant difference in FAZ area measurements between Angiovue and Angioplex. 20 Other comparison studies involving devices not included in this study did not demonstrate consistency in FAZ area measurements across devices. While Al-Sheikh et al revealed good repeatability for FAZ area between machines, Mihailovic et al and Corvi et al found significantly different FAZ areas across devices. 11, 18, 19 In their study evaluating twenty eyes with diabetic retinopathy, Chung et al suggested that there was no significant difference in the VD between Angioplex and Angiovue. 20 However, a study conducted by Munk et al, which imaged nineteen healthy subjects on four OCT-A machines (Angiovue, Triton, Angioplex, and Spectralis), revealed that Angioplex offers the best preservation of vessel continuity in both SCP and DCP. 3 In particular, this finding may explain the significantly greater VD observed with Angioplex when compared to Angiovue or Triton. Discrepancies in VD between devices may also be related to differences in automated segmentation of the superficial and deep capillary layers. In addition, due to the lack of standardization in image processing methods and binarization algorithms, VD between studies unfortunately cannot be compared.
The presented study does have limitations that should be considered. One limitation is that all study subjects had chorioretinal diseases which could have affected the image quality of the retinal vasculature. This limitation would not be present if only healthy eyes were included, but the study results would be less applicable to OCT-A use in everyday retina practice or a clinical trial investigating retinal diseases. Secondly, the current study had a small sample size of thirteen eyes and not all scans were captured on the same day. As a result, a larger prospective study is needed to validate the conclusions of this pilot study. In conclusion, the quantitative comparisons of the Angiovue, Triton and Angioplex OCT-A devices showed strong consistency for FAZ area measurements. However, significant differences were found in the VD measurements across devices. Clinicians should exercise caution when comparing SCP and DCP VD metrics among devices.
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